Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

with advanced or refractory cancers expressing DLL3. A Phase I clinical trial of PT217 is also ongoing in China (CTR20242720). Earlier this year, Phanes entered into a clinical supply agreement with Roche to study PT217 in combination with Roche's...

LEQEMBI® (lecanemab), a treatment for Alzheimer's disease, is now available in South Korea, expanding access to innovative care

"LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia (early...

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

NS Pharma, Inc. announced a change of leadership within its Commercial division. Effective September 9, 2024, Donald Foy – who had previously served as national sales director – was appointed to the role of vice president, Commercial. Jennifer...

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

often nonfunctional protein and effectively causing a loss of function. Their study appeared online on November 01, 2024 in the journal Experimental & Molecular Medicine. Highlighting the significance of this achievement, senior author Prof. Lee...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

compliant marketing. Axonal.AI was founded by Larry Mickelberg, who was named earlier this year as one of MM+M Magazine’s 2024 Top Healthcare Marketing Influencers. With over 20 years of leadership experience at leading management consultancies and...

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand...

HanAll Biopharma releases Q3 2024 financial results and shares business updates

to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates. HanAll ended the third quarter with total revenue of 36.8 billion KRW, reflecting an 11.7%...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2024 there will be 299,310 new cases of prostate cancer in the US and around 35,250 deaths from the disease[2]. About Clarity...

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Eisai Saudi Arabia was established in April 2024 in order to build an in-house sales system. Japan-based Eisai Co. has announced that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited...

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

in Patients with Prostate Cancer: A Comprehensive Systematic Review and Meta analysis." Journal of Nuclear Medicine (2024). About Radiohybrid Prostate‐Specific Membrane Antigen (rhPSMA): rhPSMA compounds are referred to as radiohybrid ("rh"), as...

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

scientific challenges, enabling researchers to make meaningful advances in their fields. Promega invites attendees of SFN 2024 to Booth #1316 to experience live demonstrations of the Glomax® Galaxy, showcasing its potential to transform research....

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

weight loss but also maintain the strength and energy they need for a healthy life." The study is set to start December 2024 at the nuHx headquarters in West Palm Beach and conclude May 2025 with published study results to follow. nuBioAge and its...

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

the Phase 1 trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in early November 2024. The Phase 1 trial is conducted in collaboration with Cleveland Clinic and is funded by a grant from the U.S. Department of...

Bloomage 2024 Mid-Year Report: International raw material sales exceed domestic Chinese market sales for the first time

and other bioactive substance innovations, showcased robust growth in its raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue of RMB 2.811 billion (~ USD 393.54 million) for the first...

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

will hold an advisory committee meeting with the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on October 10, 2024 to evaluate the New Drug Application (NDA) for elamipretide, the first potential therapy for Barth syndrome. This...

Lunit joins Roche's Digital Pathology Open Environment to advance cancer biomarker testing

of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast...

Genprex collaborators to present positive preclinical data on Reqorsa® gene therapy

for patients with cancer and diabetes, announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The collaborators will present posters on positive...

Onco360 now offers LAZCLUZE™ (lazertinib) with Rybrevant® for first-line treatment of metastatic non-small cell lung cancer with specific EGFR mutations

Epidemiology, and End Results (SEER) Program, approximately 234,580 patients will be diagnosed with lung cancer in 2024, accounting for 11.7% of all new cancer cases, with approximately 125,070 expected patient deaths from prostate cancer in 2024,...

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

in a timely, safe and convenient way.” This year, the CDC recommends everyone ages 6 months and older receive updated 2024-2025 COVID-19 and flu vaccines, with rare exceptions. The CDC says that the concurrent administration of both vaccines is...

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

CVS Health® announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has...

Results 81 - 100 of 136